$87.77 Million in Sales Expected for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) This Quarter

Equities research analysts expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMYGet Rating) to report sales of $87.77 million for the current quarter, according to Zacks. Four analysts have issued estimates for Harmony Biosciences’ earnings, with estimates ranging from $86.88 million to $88.80 million. Harmony Biosciences reported sales of $59.67 million during the same quarter last year, which would suggest a positive year over year growth rate of 47.1%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Harmony Biosciences will report full-year sales of $429.99 million for the current year, with estimates ranging from $414.77 million to $443.20 million. For the next fiscal year, analysts expect that the firm will post sales of $604.57 million, with estimates ranging from $569.90 million to $665.40 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Harmony Biosciences.

Harmony Biosciences (NASDAQ:HRMYGet Rating) last posted its earnings results on Monday, February 28th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.02. Harmony Biosciences had a return on equity of 75.85% and a net margin of 11.33%. During the same period in the previous year, the firm earned $0.25 EPS.

Separately, Zacks Investment Research upgraded shares of Harmony Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, March 2nd.

In related news, Director Jack Nielsen sold 1,027 shares of Harmony Biosciences stock in a transaction on Monday, April 4th. The shares were sold at an average price of $50.00, for a total transaction of $51,350.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO John C. Jacobs sold 15,000 shares of Harmony Biosciences stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $45.32, for a total transaction of $679,800.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 617,757 shares of company stock valued at $27,338,731. Insiders own 28.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Advisor Group Holdings Inc. raised its position in shares of Harmony Biosciences by 352.2% during the 4th quarter. Advisor Group Holdings Inc. now owns 615 shares of the company’s stock valued at $28,000 after buying an additional 479 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Harmony Biosciences in the 4th quarter worth about $84,000. Royal Bank of Canada raised its position in Harmony Biosciences by 242.2% in the 2nd quarter. Royal Bank of Canada now owns 2,293 shares of the company’s stock worth $65,000 after purchasing an additional 1,623 shares during the period. Citigroup Inc. raised its position in Harmony Biosciences by 36.6% in the 3rd quarter. Citigroup Inc. now owns 2,931 shares of the company’s stock worth $112,000 after purchasing an additional 785 shares during the period. Finally, Mutual of America Capital Management LLC purchased a new stake in Harmony Biosciences in the 4th quarter worth about $133,000. Institutional investors and hedge funds own 53.82% of the company’s stock.

Shares of NASDAQ HRMY traded down $2.64 during trading hours on Monday, hitting $47.15. The company’s stock had a trading volume of 448,365 shares, compared to its average volume of 398,214. The company has a debt-to-equity ratio of 1.02, a quick ratio of 5.21 and a current ratio of 5.29. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 81.29 and a beta of 0.51. Harmony Biosciences has a 12 month low of $25.09 and a 12 month high of $52.75. The business has a 50-day simple moving average of $43.79 and a 200-day simple moving average of $40.72.

About Harmony Biosciences (Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Featured Articles

Get a free copy of the Zacks research report on Harmony Biosciences (HRMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.